title: The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study.
abstract: The purpose of this study was to assess the effects of a commercially available weight loss program on weight and glycemic control among obese patients with type 2 diabetes. Participants included 69 patients (49 females, 20 males) with type 2 diabetes who had a mean +/- SD age of 52.2 +/- 9.5 years, a body mass index of 39.0 +/- 6.2 kg/m(2), and hemoglobin A1c (HbA1c) of 7.5 +/- 1.6%. Over half (52.2%) of the participants were African American. Participants were randomly assigned to: 1) a portion-controlled diet (NutriSystem D) (PCD) or 2) a diabetes support and education (DSE) program. After the initial 3 months, the PCD group continued on the PCD for the remaining 3 months, and the DSE group crossed over to PCD for the remaining 3 months. The primary comparison for this study was at 3 months. At 3 months, the PCD group lost significantly more weight (7.1 +/- 4%) than the DSE group (0.4 +/- 2.3%) (P < 0.0001). From 3 to 6 months the change in weight for both groups was statistically significant. After 3 months, the PCD group had greater reductions in HbA1c than the DSE group (-0.88 +/- 1.1 vs 0.03 +/- 1.09; P < 0.001). From 3 to 6 months the PCD group had no further change in HbA1c, while the DSE group showed a significant reduction. These data suggest that obese patients with type 2 diabetes will experience significant improvements in weight, glycemic control, and cardiovascular disease risk factors after the use of a commercially available weight management program.
authors.affiliation: Center for Obesity Research and Education, Temple University, Philadelphia, PA 19140, USA. gfoster@temple.edu
authors.forename: Gary D
authors.initials: GD
authors.lastname: Foster
authors.forename: Kelley E
authors.initials: KE
authors.lastname: Borradaile
authors.forename: Stephanie S
authors.initials: SS
authors.lastname: Vander Veur
authors.forename: Kerri
authors.initials: K
authors.lastname: Leh Shantz
authors.forename: Rebecca J
authors.initials: RJ
authors.lastname: Dilks
authors.forename: Edie M
authors.initials: EM
authors.lastname: Goldbacher
authors.forename: Tracy L
authors.initials: TL
authors.lastname: Oliver
authors.forename: Caitlin A
authors.initials: CA
authors.lastname: Lagrotte
authors.forename: Carol
authors.initials: C
authors.lastname: Homko
authors.forename: Wayne
authors.initials: W
authors.lastname: Satz
mesh_terms: D000328:Adult; D000368:Aged; D000886:Anthropometry; D001521:Behavior Therapy; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D009765:Obesity / Q000150:complications* / Q000534:rehabilitation*; D011615:Psychotherapy, Group; D011788:Quality of Life; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D015431:Weight Loss
chemical_list: D002784:Cholesterol; D006442:Glycated Hemoglobin; D014280:Triglycerides; C517652:hemoglobin A1c protein, human